2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.
Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.
The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.
There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.
Related Content: